KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 125 filers reported holding KEROS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,787,221 | -17.1% | 212,899 | +4.5% | 0.00% | -50.0% |
| Q2 2023 | $8,183,983 | +8.1% | 203,683 | +14.9% | 0.00% | 0.0% |
| Q1 2023 | $7,569,429 | -9.8% | 177,270 | +1.4% | 0.00% | 0.0% |
| Q4 2022 | $8,392,168 | +36.9% | 174,764 | +7.3% | 0.00% | +100.0% |
| Q3 2022 | $6,130,000 | +47.4% | 162,947 | +8.3% | 0.00% | 0.0% |
| Q2 2022 | $4,158,000 | -48.5% | 150,501 | +1.3% | 0.00% | 0.0% |
| Q1 2022 | $8,076,000 | -10.5% | 148,517 | -3.7% | 0.00% | 0.0% |
| Q4 2021 | $9,020,000 | +52.4% | 154,172 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $5,918,000 | -10.1% | 149,620 | -3.4% | 0.00% | 0.0% |
| Q2 2021 | $6,580,000 | -16.4% | 154,938 | +21.2% | 0.00% | 0.0% |
| Q1 2021 | $7,871,000 | -17.5% | 127,870 | -5.5% | 0.00% | -50.0% |
| Q4 2020 | $9,540,000 | +196.7% | 135,241 | +62.3% | 0.00% | +100.0% |
| Q3 2020 | $3,215,000 | -2.2% | 83,346 | -4.9% | 0.00% | 0.0% |
| Q2 2020 | $3,288,000 | – | 87,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |